In a recent study published in The New England Journal of Medicine, researchers used the TOGETHER platform trial protocol to perform a phase III randomized controlled trial (RCT) to evaluate the ...

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

WARMINSTER, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology ...

A patient presents with hepatitis C coinfected with uncomplicated HIV. CD4+ cell counts are low normal and alanine aminotransferase levels are not elevated. HIV treatment is not indicated, but should ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A single dose of pegylated interferon lambda used as ...

Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...

In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to why lupus symptoms and severity present differently in individuals with the autoimmune condition, which ...

Early interferon therapy reduces secondary myelofibrosis risk in young ET and PV patients. Cytoreductive drugs do not lower thrombotic event risk in young patients. Elevated white blood cell counts ...

In 1980, TIME Magazine wrote about interferon as the “if” drug for cancer. Promising studies sparked widespread hope around the potential of the interferon to treat cancer, only if it could deliver ...